DBV Technologies S.A. SEC filings DBVTF
DBV Technologies S.A. has 576 filings in SEC EDGAR's recent list, going back to Jul 25, 2014. Its latest annual report, Form ARS, was filed on May 11, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 28, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | May 29, 2025 | — |
| CORRESP | Letter to the SEC | May 27, 2025 | — |
| UPLOAD | Letter from the SEC | May 23, 2025 | — |
| D | Filing | Apr 17, 2025 | — |
| NT 10-K | Filing | Mar 31, 2025 | Dec 31, 2024 |
| EFFECT | Filing | Apr 17, 2023 | — |
| CORRESP | Letter to the SEC | Apr 13, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 13, 2023 | — |
| EFFECT | Filing | Aug 11, 2022 | — |
| EFFECT | Filing | Aug 11, 2022 | — |
| CORRESP | Letter to the SEC | Aug 9, 2022 | — |
| CORRESP | Letter to the SEC | Aug 9, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 5, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 5, 2022 | — |
| PRER14A | Filing | Apr 14, 2022 | — |
| EFFECT | Filing | Jul 16, 2021 | — |
| EFFECT | Filing | Oct 1, 2019 | — |
| CORRESP | Letter to the SEC | Sep 27, 2019 | — |
| UPLOAD | Letter from the SEC | Sep 12, 2019 | — |
| CT ORDER | Filing | Apr 30, 2019 | — |
| EFFECT | Filing | Apr 9, 2019 | — |
| POSASR | Filing | Apr 1, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 5, 2018 | — |
| CORRESP | Letter to the SEC | Dec 14, 2017 | — |
| UPLOAD | Letter from the SEC | Nov 14, 2017 | — |
| CT ORDER | Filing | May 15, 2017 | — |
| EFFECT | Filing | Jul 14, 2015 | — |
| UPLOAD | Letter from the SEC | Jul 13, 2015 | — |
| CORRESP | Letter to the SEC | Jul 10, 2015 | — |
| CORRESP | Letter to the SEC | Jul 10, 2015 | — |
| CERTNAS | Auto-generated paper document | Oct 21, 2014 | — |
| EFFECT | Filing | Oct 21, 2014 | — |
| EFFECT | Filing | Oct 21, 2014 | — |
| CORRESP | Letter to the SEC | Oct 17, 2014 | — |
| 8-A12B | Filing | Oct 17, 2014 | — |
| CORRESP | Letter to the SEC | Oct 17, 2014 | — |
| CORRESP | Letter to the SEC | Oct 17, 2014 | — |
| CORRESP | Letter to the SEC | Oct 7, 2014 | — |
| UPLOAD | Letter from the SEC | Oct 3, 2014 | — |
| UPLOAD | Letter from the SEC | Sep 15, 2014 | — |
| DRS/A | Filing | Aug 29, 2014 | — |
| UPLOAD | Letter from the SEC | Aug 21, 2014 | — |
| DRS | Filing | Jul 25, 2014 | — |
Showing 43 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- DBVT (Nasdaq), DBVTF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- France
- Headquarters
- Chatillon
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1613780
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.